Consensus Ultimovacs ASA

Equities

ULTI

NO0010851603

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-06 am EDT			5-day change	1st Jan Change
7.77 ^NOK	+10.06%		+11.64%	-93.67%

Apr. 17	Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments	MT
Apr. 17	Transcript : Ultimovacs ASA - Special Call

Evolution of the average Target Price on Ultimovacs ASA

Price target over the last 5 years

History of analyst recommendation changes

41c85e36ae9b5cf241a2dd58cf1c0.nNWd1XccMTxGUwE92hfec3KvfD68rXEtkZAQCFpQtps.64zk5TEpYVMAB0JYu3PmOwDmGnWJxkdjw_t8a2tl2azUvditJ15SRBYRcg~a01100b850ecaf5e5d5e89ead312ecf5

Analyst Recommendations on Ultimovacs ASA

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma	22-10-05	CI
Ultimovacs : Cancer Vaccine Trial Shows 90% Survival Rate	21-08-12	MT
Ultimovacs ASA’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data	21-05-19	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

7.06 NOK

Average target price

6.5 NOK

Spread / Average Target

-7.93%

High Price Target

9 NOK

Spread / Highest target

+27.48%

Low Price Target

4 NOK

Spread / Lowest Target

-43.34%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar